Anti-epileptic	anti-epileptic	O	O	O	O
drugs-induced	drugs-induced	O	O	O	O
de	de	O	O	O	O
novo	novo	O	O	O	O
absence	absence	O	O	OTHERS	I
seizures	seizures	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
authors	authors	O	O	O	O
present	present	O	O	O	O
three	three	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
de	de	O	O	O	O
novo	novo	O	O	O	O
absence	absence	O	O	OTHERS	I
epilepsy	epilepsy	O	DISEASE	OTHERS	I
after	after	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
carbamazepine	carbamazepine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
vigabatrin	vigabatrin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Despite	despite	O	O	O	O
the	the	O	O	O	O
underlying	underlying	O	O	O	O
diseases	diseases	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
prognosis	prognosis	O	O	O	O
for	for	O	O	O	O
drug-induced	drug-induced	O	O	O	O
de	de	O	O	O	O
novo	novo	O	O	O	O
absence	absence	O	O	OTHERS	I
seizure	seizure	O	DISEASE	OTHERS	I
is	is	O	O	O	O
good	good	O	O	O	O
because	because	O	O	O	O
it	it	O	O	O	O
subsides	subsides	O	O	O	O
rapidly	rapidly	O	O	O	O
after	after	O	O	O	O
discontinuing	discontinuing	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
offending	offending	O	O	O	O
drugs	drugs	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
gamma-aminobutyric	gamma-aminobutyric	O	O	O	O
acid-transmitted	acid-transmitted	O	O	O	O
thalamocortical	thalamocortical	O	O	O	O
circuitry	circuitry	O	O	O	O
accounts	accounts	O	O	O	O
for	for	O	O	O	O
a	a	O	O	O	O
major	major	O	O	O	O
part	part	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
underlying	underlying	O	O	O	O
neurophysiology	neurophysiology	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
absence	absence	O	O	OTHERS	I
epilepsy	epilepsy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Because	because	O	O	O	O
drug-induced	drug-induced	O	O	O	O
de	de	O	O	O	O
novo	novo	O	O	O	O
absence	absence	O	O	OTHERS	I
seizure	seizure	O	DISEASE	OTHERS	I
is	is	O	O	O	O
rare	rare	O	O	O	O
,	,	O	O	O	O
pro-absence	pro-absence	O	O	O	O
drugs	drugs	O	O	O	O
can	can	O	O	O	O
only	only	O	O	O	O
be	be	O	O	O	O
considered	considered	O	O	O	O
a	a	O	O	O	O
promoting	promoting	O	O	O	O
factor	factor	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
underlying	underlying	O	O	O	O
epileptogenecity	epileptogenecity	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
or	or	O	O	O	O
the	the	O	O	O	O
synergistic	synergistic	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
accompanying	accompanying	O	O	O	O
drugs	drugs	O	O	O	O
is	is	O	O	O	O
required	required	O	O	O	O
to	to	O	O	O	O
trigger	trigger	O	O	O	O
the	the	O	O	O	O
de	de	O	O	O	O
novo	novo	O	O	O	O
absence	absence	O	O	OTHERS	I
seizure	seizure	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
possibility	possibility	O	O	O	O
of	of	O	O	O	O
drug-induced	drug-induced	O	O	O	O
aggravation	aggravation	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
considered	considered	O	O	O	O
whenever	whenever	O	O	O	O
an	an	O	O	O	O
unexpected	unexpected	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
seizure	seizure	O	DISEASE	OTHERS	I
frequency	frequency	O	O	O	O
and/or	and/or	O	O	O	O
new	new	O	O	O	O
seizure	seizure	O	DISEASE	OTHERS	I
types	types	O	O	O	O
appear	appear	O	O	O	O
following	following	O	O	O	O
a	a	O	O	O	O
change	change	O	O	O	O
in	in	O	O	O	O
drug	drug	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

By	by	O	O	O	O
understanding	understanding	O	O	O	O
the	the	O	O	O	O
underlying	underlying	O	O	O	O
mechanism	mechanism	O	O	O	O
of	of	O	O	O	O
absence	absence	O	O	OTHERS	I
epilepsy	epilepsy	O	DISEASE	OTHERS	I
,	,	O	O	O	O
we	we	O	O	O	O
can	can	O	O	O	O
avoid	avoid	O	O	O	O
the	the	O	O	O	O
inappropriate	inappropriate	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
anticonvulsants	anticonvulsants	O	O	O	O
in	in	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
epilepsy	epilepsy	O	DISEASE	OTHERS	I
and	and	O	O	O	O
prevent	prevent	O	O	O	O
drug-induced	drug-induced	O	O	O	O
absence	absence	O	O	OTHERS	I
seizures	seizures	O	DISEASE	OTHERS	I
.	.	O	O	O	O

